Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pharyngitis01:30

Acute Pharyngitis

Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adherence With Diagnostic Stewardship Guidance and Sociodemographic Characteristics in the PICU.

Hospital pediatrics·2026
Same author

Implementation of a Systematic Patient Mobility Program Across 5 Hospitals.

Journal of the American Medical Directors Association·2026
Same author

Gender equality and equity in intensive care: an international Delphi consensus study.

Intensive care medicine·2026
Same author

Developing Core Outcome (Measurement) Sets for Critical Care Research Using the Modified Delphi Method: A Narrative Review.

CHEST critical care·2026
Same author

A model for prevention: applying lessons from Group B Streptococcus to Staphylococcus aureus in very low birth weight neonates.

Journal of perinatology : official journal of the California Perinatal Association·2025
Same author

Quantifying Practice Variability to Inform the Design of Implementation Programs in Critical Care and Assess Their Impact.

Chest·2025

Related Experiment Videos

Ventilator-associated tracheitis in children: does antibiotic duration matter?

Pranita D Tamma1, Alison E Turnbull, Aaron M Milstone

  • 1Department of Pediatric Infectious Diseases, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA. ptamma1@jhmi.edu

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|May 5, 2011
PubMed
Summary

Prolonged antibiotic treatment for ventilator-associated tracheitis (VAT) does not prevent hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP). Longer antibiotic courses increase the risk of multidrug-resistant organism (MDRO) acquisition.

Related Experiment Videos

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Pediatric Pulmonology

Background:

  • The optimal duration of antibiotic therapy for ventilator-associated tracheitis (VAT) remains undefined.
  • Prolonged antibiotic courses may lead to unnecessary treatment durations.
  • Current guidelines lack clear recommendations on VAT antibiotic duration.

Purpose of the Study:

  • To compare the efficacy of prolonged-course (≥7 days) versus short-course (<7 days) antibiotic therapy for VAT in preventing progression to hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP).
  • To assess the association between prolonged-course antibiotic therapy for VAT and the acquisition of multidrug-resistant organisms (MDROs).

Main Methods:

  • Retrospective cohort study involving pediatric patients (≤18 years) requiring mechanical ventilation for ≥48 hours.
  • Analysis of patients who received antibiotic therapy for clinician-suspected VAT between January 2007 and December 2009.
  • Comparison of outcomes, including HAP/VAP development and MDRO acquisition, between short-course and prolonged-course antibiotic groups.

Main Results:

  • Prolonged-course antibiotics for VAT did not demonstrate a protective effect against subsequent HAP or VAP (HR, 1.08; 95% CI, 0.40-2.91).
  • Factors associated with increased risk of MDRO colonization or infection included prolonged-course antibiotic therapy (HR, 5.15; 95% CI, 1.54-7.19), combination antibiotic therapy (HR, 3.24; 95% CI, 1.54-6.82), and longer hospital exposure.
  • Only 118 out of 150 patients initially treated for VAT met the study's criteria for VAT.

Conclusions:

  • Extended antibiotic therapy for VAT does not offer additional protection against HAP or VAP compared to shorter courses.
  • Prolonged antibiotic use for VAT is significantly associated with an increased risk of acquiring multidrug-resistant organisms.
  • Clinical practice should consider shorter antibiotic durations for VAT to mitigate MDRO risks.